Advertisement BioPartners - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

BioPartners

Developing Biologics, Delivering Patient Care

Logo
LATEST PRESS RELEASES
June 10, 2010

Biopartners Receives EU Marketing Authorisation for Ribavirin Biopartners 200mg Film-Coated Tablet for Chronic Hepatitis C

On 8 April 2010 Biopartners GmbH announced that it had received EU marketing authorisation from the European Commission for Ribavirin...
pharmacuetical business review


LATEST VIDEOS

BioPartners

Established in 2000, Biopartners' aim is to be a leader in developing and commercialising innovative formulations and novel delivery systems of first-generation biopharmaceuticals for which there are substantial unmet medical/patients' needs.

Biopartners seeks to offer safe, efficacious and competitively priced biopharmaceutical therapies. Its product portfolio covers the fields of endocrinology, multiple sclerosis and virology.

With its head office located in Switzerland, and an affiliate located in Germany, Biopartners is building an international network through a series of collaborations and partnerships with leading development and service partners. Biopartners is in the process of negotiating commercial agreements with major companies for the distribution of products in all relevant markets.

Developing biopharmaceutical products in the fields of endocrinology, multiple sclerosis and virology

Biopartners is dedicated to improving quality of life through significant advancements in patient care. We are a dynamic and growing biopharmaceutical company, leading the development of biopharmaceutical products in the fields of endocrinology, multiple sclerosis and virology. Our comprehensive product portfolio consists of first-generation biopharmaceuticals with innovative-formulations or novel delivery systems.

Once-a-week human growth hormone treatment with an innovative prolonged release formulation

We are on track to be the first company to submit a prolonged-release formulation of recombinant human growth hormone (rhGH) which will cut the number of self-administered injections from once-a-day to once-a-week – a major breakthrough in hGH treatment.

Biopartners is owned by Bioton S.A, a dynamically-growing Polish biotechnology company, manufacturing clinically important drugs such as recombinant human insulin.

BioPartners GmbH
Sihlbruggstrasse 3
6340 Baar
Switzerland

Tel: +41 41 766 20 80
Fax: +41 41 766 20 81
info@Biopartners.ch
www.biopartners.com

Biosimilars

Valtropin® recombinant human growth hormone.

Valtropin Status: Approved by EMA. Human growth hormone (hGH) is secreted by a specialised structure in the brain, the pituitary; it not only induces growth, but also regulates important metabolic effects. Valtropin® is Biopartners' biosimilar rhGH for the treatment of growth hormone deficiency and Turner's Syndrome. Valtropin® is administered as a daily injection and its…

Innovative Biopharmaceuticals

Biopartners' aim is to be a leader in developing and commercializing biopharmaceuticals for which there are substantial unmet patients/medical needs. This strategy involves bringing to market both innovative formulations and/or novel delivery systems of first-generation biopharmaceuticals.

Once-a-week prolonged release recombinant human growth hormone Status: Late Phase III clinical development. Human growth hormone (hGH) is secreted by a specialised structure in the brain, the pituitary; it not only induces growth, but also regulates important metabolic effects. Recombinant human growth hormone (rhGH) therapies have been successfully used to treat growth hormone deficiencies for…

Chemically Derived Pharmaceuticals

Ribavirin BioPartners As a standard treatment, Ribavirin is indicated for use in combination with Interferon Alpha to treat chronic Hepatitis C (HCV) infection. Ribavirin is a chemically derived pharmaceutical and belongs to a class of drugs called nucleoside analogues.

Status: Approved by EMA Ribavirin is a chemically-derived synthetic analogue of guanosine that has a broad spectrum anti-viral effect by inhibiting RNA polymerase of various RNA viruses. Biopartners has developed a patented, coated tablet formulation of ribavirin, which is a tablet for daily use, solely in combination with interferon alpha for the treatment of chronic,…
Quick Contact BioPartners
Quick Contact BioPartners
Quick Contact BioPartners


Quick Contact BioPartners
Quick Contact BioPartners
Quick Contact BioPartners


Contact BioPartners

Optional Data

Almost there, complete this form and hit the submit button to complete your registration.

Confirmation

Finally, complete a quick security check and confirm terms and conditions:

Quick Contact BioPartners